RAPT
RAPT Therapeutics, Inc.No price
Median target
$58.00
range $58.00–58.00
Insider net
$0
no open-market trades · since Mar 3
New fund stakes
0
Q1 2026 13F · 3 exits
Filing reports
1
analyzed by SecBot
SecBot read MIXED 1 report · latest
Balance 0 bearish · 0 bullish · 1 neutral oldest → newest, height = score
Avg score ·High conf. 1/1
Price
Daily candles with volume.
No data for this timeframe.
Signal stack
Where each data set points today.
- InsidersNO TRADES
No open-market buys or sells since Mar 3. Recent filings are awards, exercises and tax withholding.
- InstitutionsBEARISH
Q1 2026: 0 added (0 new), 3 trimmed or exited.
- EstimatesFALLING
Current-quarter EPS estimate −$0.762 → −$1.027 over 90 days.
Who's buying
13F· Q1 20260
new positions
3
exits
| Fund | Move | Value |
|---|---|---|
| STATE STREET CORP | EXIT | $0.00 |
| RTW INVESTMENTS, LP | EXIT | $0.00 |
| BlackRock, Inc. | EXIT | $0.00 |
| VANGUARD GROUP INC | ADD | $40.2M |
| STATE STREET CORP | DOUBLED | $21.7M |
| BlackRock, Inc. | DOUBLED | $16.5M |
| GOLDMAN SACHS GROUP INC | DOUBLED | $8.6M |
| GEODE CAPITAL MANAGEMENT, LLC | ADD | $8.1M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
Last action Jan 2026Recent actions
| Date | Firm | Rating |
|---|---|---|
| Jan 21, 2026 | Barclays DOWNGRADE | Equal-Weight |
| Jan 21, 2026 | Leerink Partners DOWNGRADE | Market Perform |
| Jan 20, 2026 | Wells Fargo DOWNGRADE | Equal-Weight |
| Jan 20, 2026 | LifeSci Capital DOWNGRADE | Market Perform |
| Jan 20, 2026 | TD Cowen DOWNGRADE | Hold |
| Jan 20, 2026 | HC Wainwright & Co. DOWNGRADE | Neutral |
Insider ledger
Form 4$0
open-market buys or sells · since Mar 3
| Insider | Type | Value |
|---|---|---|
Lyons-Williams Lori Director Mar 3, 2026 | TO ISSUER | 2,813 sh |
GRAY MARY ANN Director Mar 3, 2026 | TO ISSUER | 1,072 sh |
GRAY MARY ANN Director Mar 3, 2026 | TO ISSUER | 1,618 sh |
Brockstedt Dirk G. CHIEF SCIENTIFIC OFFICER Mar 3, 2026 | TO ISSUER | 6,250 sh |
Giordano Michael F Director Mar 3, 2026 | TO ISSUER | 4,561 sh |
Giordano Michael F Director Mar 3, 2026 | TO ISSUER | 1,063 sh |
Braunstein Scott Director Mar 3, 2026 | TO ISSUER | 25,000 sh |
Brockstedt Dirk G. CHIEF SCIENTIFIC OFFICER Mar 3, 2026 | TENDER | 4,648 sh |
Earnings setup
Estimates−$1.03
EPS estimate, this quarter
−35%
estimate change, 90 days
Current-quarter EPS estimate
−$0.76290d
−$0.83960d
−$0.88330d
−$0.8837d
−$1.027Now
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Next Q | -$0.57 | -$0.72–-$0.43 | +12.5% | $0.00 |
| Current Q | -$1.03 | -$1.30–-$0.83 | -16.2% | $0.00 |
| Current FY | -$2.83 | -$2.95–-$2.74 | -14.3% | $0.00 |
| Next FY | -$2.71 | -$3.26–-$1.77 | +12.6% | $0.00 |
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Aug 5, 2026 Earnings calendar
RAPT Q2 2026 Earnings Scheduled, 2026-08-05
Mar 31, 2026 Inst.
STATE STREET CORP · EXIT
0 shares ($0.00)
Mar 31, 2026 Inst.
Mar 18, 2026 SEC RTW INVESTMENTS, LP · EXIT
0 shares ($0.00)
RAPT Therapeutics has filed Form 15 to terminate its SEC registration and suspend reporting obligations following its…
15-12G · Impact 7/10
Mar 3, 2026 Insider
Lyons-Williams Lori disposed of 2,813 shares
Director
Mar 3, 2026 Insider
GRAY MARY ANN disposed of 1,072 shares
Director
Mar 3, 2026 Insider
GRAY MARY ANN disposed of 1,618 shares
Director
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Sep 3, 2026
Clinical Trial
Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab
Phase 2 · COMPLETED
Aug 5, 2026
Earnings date
RAPT Q2 2026 Earnings Scheduled, 2026-08-05
May 6, 2026
Earnings date
RAPT Q1 2026 Earnings Scheduled, 2026-05-06
Mar 23, 2026
Clinical Trial
An Efficacy and Safety Study of RPT193 in Adults With Atopic Dermatitis
Phase 2 · TERMINATED
Mar 23, 2026
Clinical Trial
Phase 2 Study to Evaluate RPT193 in Adults With Moderate to Severe T2-high Asthma
Phase 2 · TERMINATED
SecBot reports
1 filing · 0 bullish · 0 bearish · 1 neutralAll RAPT filing & press-release reports (1)
- 15-12G reportMar 18, 2026